For research use only.

Catalog No.S7010

18 publications

GDC-0152 Chemical Structure

CAS No. 873652-48-3

GDC-0152 is a potent antagonist of XIAP-BIR3, ML-IAP-BIR3, cIAP1-BIR3 and cIAP2-BIR3 with Ki of 28 nM, 14 nM, 17 nM and 43 nM in cell-free assays, respectively; less affinity shown to cIAP1-BIR2 and cIAP2-BIR2. Phase 1.

Size Price Stock Quantity  
USD 270 In stock
USD 1670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's GDC-0152 has been cited by 18 publications

3 Customer Reviews

  • Inhibitor of Apoptosis Proteins (IAPs) were involved in MCP-1/IL-6 production under high dose TNF-α stimulation. A. hUC-MSCs (2x104 in 96-well plates) were pretreated for 2h with the IAP inhibitor GDC-0152 at increasing concentrations (0-1000 nM), then stimulated with TNF-α (20 ng/ml, 1.2 nM). After a further 24h, trypan blue was used to exclude cell toxicity. SN was collected and IL-6 and MCP-1 concentrations were measured by ELISA. B. hUC-MSCs(5×105 in T25 bottle) were pretreated with GDC-0152(1000nM) for 2 h, then stimulated with TNF-α (20 ng/ml, 1.2 nM). 24 hours later, protein from nucleus and cytoplasma were extracted separately and the amount of NF-kB were detected by Western blot. Data are as mean±SEM of triplicate measurements; *p<0.05, **p<0.01, ***p<0.001 when compared to untreated cells. These experiments were repeated 3 times with the same results, using clone 69 and another TNF-α sensitive clone (clone 120003).

    PLoS One, 2015, 10(5):e0128647.. GDC-0152 purchased from Selleck.

  • (a) Apoptosis (SubG0/G1) of DMSO control and GDC-0152-treated cells was determined by flow cytometry of propidium iodide-stained nuclei and percentage of apoptosis is shown. U87MG and GL261 cell lines were treated for 72 h and GBM6 and GBM9 cell lines were treated for 8 days at the indicated concentrations. At these respective time points, percentage of U87MG cells dead by apoptosis, percentage of GL261 cells, percentage of GBM6 cells and percentage of GBM9 cells. Data are expressed as mean+S.E.M. Three independent experiments were performed for the GL261 cell lines and five for the U87MG, GBM6 and GBM9 cell lines. *P<0.05; **P<0.01; ***P<0.005.

    Cell Death Dis, 2016, 7(8):e2325. GDC-0152 purchased from Selleck.

  • GDC-0152 sensitises FTC cell lines for TRAIL-induced apoptosis. FTC cell lines were treated with increasing concentrations of rh-TRAIL with and without Smac mimetics GDC-0152. Changes in cell viability are illustrated linearly in percentage control and stratified according to the FP. While FTC cell line TT2609-bib2 was susceptible to rh-TRAIL alone (C), cell line FTC133 proved to be resistant to rh-TRAIL-induced apoptosis (D). Smac mimetic treatment alone had no impact on cell viability. Annexin V/PI staining and FACS analyses of FTC cells demonstrate the changes of annexin positive apoptotic cells after incubation with rh-TRAIL alone (−) or in combination (+) with Smac mimetics Birinapant GDC-0152 (C/D). Changes in protein expression of cIAP1/2 after treatment with the respective Smac mimetic are illustrated using Western blot. GAPDH served as loading control. Blots are cropped to increase clarity. Statistical significance was calculated by two-tailed nonparametric Mann–Whitney test. e. survival:expected survival; sp. survival: specific survival; FP: fractional product; *P < 0.05; **P < 0.01.

    Endocr Relat Cancer, 2018, 25(3):295-308. GDC-0152 purchased from Selleck.

Purity & Quality Control

Choose Selective IAP Inhibitors

Biological Activity

Description GDC-0152 is a potent antagonist of XIAP-BIR3, ML-IAP-BIR3, cIAP1-BIR3 and cIAP2-BIR3 with Ki of 28 nM, 14 nM, 17 nM and 43 nM in cell-free assays, respectively; less affinity shown to cIAP1-BIR2 and cIAP2-BIR2. Phase 1.
(Cell-free assay)
cIAP1-BIR3 [1]
(Cell-free assay)
(Cell-free assay)
cIAP2-BIR3 [1]
(Cell-free assay)
(Cell-free assay)
14 nM(Ki) 17 nM(Ki) 28 nM(Ki) 43 nM(Ki) 112 nM(Ki)
In vitro

GDC-0152 can block protein−protein interactions that involve IAP proteins and pro-apoptotic molecules. Using transiently transfected HEK293T cells, GDC-0152 is shown to disrupt XIAP binding to partially processed caspase-9 and to disrupt the association of ML-IAP, cIAP1, and cIAP2 with Smac. In melanoma SK-MEL28 cells, the endogenous association of ML-IAP and Smac is effectively also abolished by GDC-0152. GDC-0152 lead to a decrease in cell viability in the MDA-MB-231 breast cancer cell line, while having no effect on normal human mammary epithelial cells (HMEC). GDC-0152 is found to activate caspases 3 and 7 in a dose- and time-dependent manner. GDC-0152 is shown to induce rapid degradation of cIAP1 in A2058 melanoma cells. It effectively induces degradation of cIAP1 at concentrations as low as 10 nM, consistent with its affinity for cIAP1.

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293T cells MXnGeY5kfGmxbjDhd5NigQ>? NIHNdZEyNTVyIN88US=> NYXlfGdiOiCq MYXJcohq[mm2aX;uJI9nKE[uYXeteIFo\2WmIGjJRXAhSkmUMzDkc41icW5iYnnu[Ilv\yC2bzDjTWFROSCneIDy[ZN{\WRiaX6gbJVu[W5iSFXLNlk{XCClZXzsd{BifCBzIITvJFUxKHWPIHHmeIVzKDJiaILzJIJ6KGmvbYXuc5Bz\WOrcHn0ZZRqd25? MYSyNlQyOzh4Mx?=
SK-MEL28 cells MU\GeY5kfGmxbjDhd5NigQ>? NUPJWolGOC53IN88US=> MWLJcohq[mm2aX;uJI9nKE2OLVnBVEBjcW6maX7nJJRwKFOvYYig[ZhxemW|c3XkJIlvKGenbXPpeIFjcW6nIHHu[EB7XkGmIITy[YF1\WRiaIXtZY4hW0tvTVXMNlgh[2WubIOgZZQhOC53IIXNJIJ6KGmvbYXuc5Bz\WOrcHn0ZZRqd25? M2n0N|IzPDF|OE[z
A2058 cells NUfJfJFjTnWwY4Tpc44h[XO|YYm= NImzSnQyPSCvaX7z MoD2TY5lfWO2aX;uJI9nKHC{b4TlZZNwdWGuIHTl[5Ji\GG2aX;uJI9nKGOLQWCxJIlvKGi3bXHuJGEzODV6IHPlcIx{KGGodHXyJFE2KG2rboOgZpkhcW2vdX7vZoxwfHSrbne= Ml\vNlI1OTN6NkO=
MDA-MB-231 cells NXPsVoYyS3m2b4TvfIlkcXS7IHHzd4F6 MYi3NkBp MofhR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwdDDhd5NigQ>? M1HMPFIzPDF|OE[z

... Click to View More Cell Line Experimental Data

Methods Test Index PMID
Western blot
cIAP1 / cIAP2 / XIAP / ML-IAP ; 

PubMed: 27490930     

Expression levels of cIAP1, cIAP2, XIAP and ML-IAP were analyzed by western blotting. Cell lines were treated with 1 μM of GDC-0152. U87MG and GL261 were treated for 72 h and GBM6 and GBM9 cell lines for 8 days. In all GBM cell lines GDC-0152 decreased IAP expression. Expression level of β-actin served as loading control. A representative experiment of three experiments is shown

In vivo GDC-0152 has moderate predicted hepatic clearance based on metabolic stability assays conducted using human liver microsomes. Plasma−protein binding of GDC-0152 is moderate and comparable among mice (88−91%), rats (89−91%), dogs (81−90%), monkeys (76−85%), and humans (75−83%) over the range of concentrations investigated (0.1−100 μM); higher plasma−protein binding is observed in rabbits (95−96%). GDC-0152 does not preferentially distribute to red blood cells with blood−plasma partition ratios ranging from 0.6 to 1.1 in all species tested. The pharmacokinetics for GDC-0152 is achieved with a C max of 53.7 μM and AUC of 203.5 h•μM. [1]


Kinase Assay:[1]
- Collapse

Fluorescence polarization-based competition assay:

Inhibition constants ( Ki ) for the antagonists are determined by addition of the IAP protein constructs to wells containing serial dilutions of the antagonists or the peptide AVPW, and the Hid-FAM probe or AVP-diPhe-FAM probe, as appropriate, in the polarization buffer. Samples are read after a 30-minute incubation. Fluorescence polarization values are plotted as a function of the antagonist concentration, and the IC50 values are obtained by fitting the data to a 4-parameter equation using software. Ki values for the antagonists are determined from the IC50 valued.
Cell Research:[1]
- Collapse
  • Cell lines: MDA-MB-231, Normal human mammary epithelial cells (HMECs)
  • Concentrations: ~1 μM
  • Incubation Time: 72 h
  • Method: MDA-MB-231 breast carcinoma cells and HMECs are treated with the indicated concentrations of GDC-0152. Cell death is assessed using the CellTiter-Glo luminescent cell viability assay 72 h following the start of treatment.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: human-tumor xenograft mouse models of MDA-MB-231 breast cancer
  • Dosages: 10, 50, or 100 mg/kg
  • Administration: oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 99 mg/mL (198.54 mM)
Ethanol 99 mg/mL (198.54 mM)
Water 3 mg/mL (6.01 mM)
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 498.64


CAS No. 873652-48-3
Storage powder
in solvent
Synonyms N/A

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00977067 Terminated Drug: GDC-0152 Solid Cancers Genentech Inc. June 2007 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IAP Signaling Pathway Map

Tags: buy GDC-0152 | GDC-0152 supplier | purchase GDC-0152 | GDC-0152 cost | GDC-0152 manufacturer | order GDC-0152 | GDC-0152 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID